Geron Corp

Most Recent

  • uploads///GERN
    Company & Industry Overviews

    Analyzing Geron’s Financial Performance

    In Q1 2018, Geron’s (GERN) license fee and royalty revenue fell YoY (year-over-year) to $318,000 from $537,000, with license fee revenue falling YoY to $248,000 from $409,000.

    By Kenneth Smith
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    How are IBB’s Subgroups Performing?

    The iShares Nasdaq Biotechnology ETF (IBB) gives good exposure to various industries in the biotechnology industry. As of October 19, IBB rose by ~0.5%.

    By Peter Neil
  • uploads///GERN
    Company & Industry Overviews

    Exploring Geron’s Financial Performance

    In fiscal 2017, Geron (GERN) generated revenues of $1 million through license fees and royalties compared with $6.1 million in fiscal 2016.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Geron: One of the Best-Performing Biotech Stocks in Past Month

    Geron (GERN) has been one of the best-performing biotechnology companies in the last month, rising 67.1% since August 10.

    By Margaret Patrick
  • uploads///medic _
    Company & Industry Overviews

    Geron Stock Rose 32% in Week Ended August 24

    On August 24, Geron (GERN) stock rose ~28.78% to $5.19 from its prior day’s close of $4.03.

    By Daniel Collins
  • uploads///GERN IMerge
    Company & Industry Overviews

    Understanding Geron Corp’s IMerge Trial

    IMerge, a two-part clinical trial, is evaluating Geron’s (GERN) imetelstat in transfusion-dependent patients with low- or intermediate-risk myelodysplastic syndromes who have relapsed after or are refractory to prior treatment with an erythropoiesis-stimulating agent.

    By Kenneth Smith
  • uploads///GERN IMbark
    Company & Industry Overviews

    A Look at Geron’s Imetelstat Research Program

    IMbark, a Phase 2 clinical trial, is evaluating two dose levels of Geron’s (GERN) imetelstat in ~200 myelofibrosis patients who have relapsed after or are refractory to prior treatment with a janus kinase inhibitor.

    By Kenneth Smith
  • uploads///GERN
    Company & Industry Overviews

    A Close Look at Geron’s Imetelstat

    Geron contributes 50% of the development costs for the imetelstat trials. Imetelstat was granted fast track designation by the FDA in October 2017.

    By Kenneth Smith
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI on a Downward Slope, but How Steep?

    On March 16, pressure on biotech and healthcare continued, with the SPDR S&P Biotech ETF (XBI) losing another 1.2% that day and closing at $48.31.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Moving Averages of XBI’s Holdings Have Improved

    The moving averages of the stocks in the SPDR S&P Biotech ETF (XBI) have seen drastic improvements recently.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.